Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, Minnesota 55905


Patients with primary systemic amyloidosis will be treated with CC-5013 (lenalidomide; Revlimid) as a single agent for 3 months. If their disease worsens or does not improve during that time frame dexamethasone will be added to the treatment program.


1. Histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy of green birefringent material in Congo red-stained tissue specimens and immunohistochemical proof of AL 2. Measurable disease of AL amyloidosis as defined by one of the following: - Serum monoclonal protein >=1.0 g by protein electrophoresis - >200 mg of monoclonal protein in the urine on 24 hour electrophoresis - Serum immunoglobulin free light chain & >=10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio 3. ECOG performance status (PS) 0, 1, 2, or 3 4. >=18 years of age 5. The following laboratory values obtained <=14 days prior to registration: - Creatinine < = 3 mg/dL - Absolute neutrophil count >=1000/microliter - Platelet >=75000/microliter - Hemoglobin > = 8.0 g/dL 6. Symptomatic organ involvement with amyloid to justify therapy. This could include liver involvement, cardiac involvement, renal involvement, peripheral neuropathy grade 1, or soft tissue involvement. Must have more than purpura or carpal tunnel syndrome 7. Previously treated or untreated. No limit to prior therapy provided there is adequate residual organ function 8. Ability to provide informed consent 9. Anticipated life expectancy of at least 3 months 10. None of the following: - Pregnant women or women of reproductive ability who are unwilling to use effective contraception - Nursing women - Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment - Myelosuppressive chemotherapy < 4 weeks prior to registration - Concomitant high dose corticosteroids - Grade 2 (or higher) peripheral neuropathy - Uncontrolled infection - Clinically overt multiple myeloma - Active malignancy - Prior hypersensitivity reaction to Thalidomide - Syncope within the past 30 days



Primary Contact:

Principal Investigator
Angela Dispenzieri, M.D.
Mayo Clinic

Backup Contact:


Location Contact:

Rochester, Minnesota 55905
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.